Monday, September 01, 2014 11:30:03 AM
EbolaCide2 may be important - if and only if they can work on it without impacting FluCide. It could provide an important proof of concept.
However, we should be aware of the following. FDA and other countries' regulations on compassionate and emergency use generally require data from GLP Regulatory Tox on multiple species of animals with PK/ADME to determine the safe and effective dosing - at a minimum. NNVC HAS NOT done this yet for even FluCide, let alone EbolaCide2 (although EC2 may potentially leverage some of FluCide data when that is done).
Maybe the situation gets desperate enough in some countries to allow use of medicines with less safety data - but that is a very long shot.
More importantly, however, EbolaCide2 could also provide another source of funds (GAs, NGAs, industry partners) to further work on Ebola and Marburg and other filoviruses that do have larger markets and may qualify for Orphan Drug status with the possibility of Priority Review Vouchers that could be worth tens to hundreds of millions of dollars to NNVC from big pharma companies.
One other possibility - share price run up for NNVC over the sensationalistic coverage of the disease with progress on EbolaCide2. However much of this would likely be from weak hands and may not result in much sustainable price increase.
Lousy Engineer quote:
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
FEATURED Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • May 17, 2024 11:00 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • BLO • May 16, 2024 8:13 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM